Article info
PDFReview
New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016
- ↵a adusumip{at}mskcc.org
- ↵b cha.edward{at}gene.com
- ↵c mcornfeld{at}iderapharma.com
- ↵d tdavis{at}celldextherapeutics.com
- ↵e ADiab{at}mdanderson.org
- ↵f tdubensky{at}aduro.com
- ↵g eevans{at}vaccinex.com
- ↵h jgrogan{at}gene.com
- ↵i birving{at}cytomx.com
- ↵j rom.leidner{at}providence.org
- ↵k olwill{at}pieris.com
- ↵l pss{at}nantworks.com
- ↵m ftriebel{at}immutep.com
- ↵n dptuck{at}gmail.com
- ↵o abot{at}kitepharma.com
- ↵p roger.dansey{at}merck.com
- ↵q cgd2139{at}cumc.columbia.edu
- ↵r gordon_freeman{at}dfci.harvard.edu
- ↵s ribrahim{at}parkerici.org
- ↵t salil.patel{at}bms.com
- ↵u chen.daniel{at}gene.com
Citation
New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016
Publication history
- Received March 27, 2017
- Accepted May 31, 2017
- First published June 20, 2017.
Online issue publication
June 20, 2017
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© The Author(s).
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.